Kausik K Ray, Fotios Barkas, Eline L Huisman, Jimmi Mathisen, Iram Faqir Muhammad, Hongye Ren, Simon Bertram Reuter, Jonathan Pearson-Stuttard, Andrew Thompson
{"title":"Association between elevated C-reactive protein and mortality, healthcare resource utilization and costs in patients with atherosclerotic cardiovascular disease and/or chronic kidney disease.","authors":"Kausik K Ray, Fotios Barkas, Eline L Huisman, Jimmi Mathisen, Iram Faqir Muhammad, Hongye Ren, Simon Bertram Reuter, Jonathan Pearson-Stuttard, Andrew Thompson","doi":"10.1093/ehjopen/oeag177","DOIUrl":"https://doi.org/10.1093/ehjopen/oeag177","url":null,"abstract":"<p><strong>Aims: </strong>Atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD) impact health and healthcare systems. Inflammation is a potential modifiable risk factor for both conditions. The case for evaluating the modification of inflammation in these conditions could be strengthened by evidence that systemic inflammation [C-reactive protein ≥2 mg/L] was associated with a considerable health burden.</p><p><strong>Methods and results: </strong>A retrospective observational cohort study of 179 261 individuals in mutually exclusive cohorts (ASCVD only, CKD stages 3-4 only, ASCVD + CKD stages 3-4) and a reference cohort (no ASCVD or CKD) with ≥1 C-reactive protein measurement after diagnosis. Outcomes included all-cause mortality, healthcare resource utilization (HCRU), and direct healthcare costs. Chronic kidney disease stages 3-4, ASCVD only, and ASCVD + CKD stages 3-4 cohorts compared with the reference cohort were associated with increasing all-cause mortality (death/100 000 person-years) of 1637, 2090, 5163, and 946, respectively. HCRU events per person per year (PPPY) and mean direct costs PPPY were 20.4, 21.4, 34.2, and 8.2 and £2593, £3098, £6810, and £1144, respectively. Within cohorts, all-cause mortality increased progressively across C-reactive protein quartiles (Q) and was highest in Q4 among the ASCVD + CKD stages 3-4 cohort, with a hazard ratio (Q4 vs. Q1) of 2.75 in this cohort compared with 1.22 in the reference cohort.</p><p><strong>Conclusion: </strong>While the clinical impact of targeting inflammation is being evaluated in ongoing trials, this real-world study demonstrates that assessing inflammation in patients with ASCVD and CKD stages 3-4 can help to identify a population with a high healthcare burden.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 6","pages":"oeag177"},"PeriodicalIF":4.3,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13756081/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149414287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comparative efficacy and safety of de-escalation, abbreviation, and standard potent P2Y<sub>12</sub> inhibitor-based dual antiplatelet therapy strategies after acute coronary syndrome: a network meta-analysis.","authors":"Yee-Jen Wu, Hung-Ju Lin, Yi-Chen Chou, Yen-Hung Lin, Chi-Sheng Hung","doi":"10.1093/ehjopen/oeag173","DOIUrl":"https://doi.org/10.1093/ehjopen/oeag173","url":null,"abstract":"<p><strong>Aims: </strong>Potent P2Y<sub>12</sub> inhibitor-based dual antiplatelet therapy (DAPT) is the default antiplatelet strategy after acute coronary syndrome (ACS), though de-escalation to clopidogrel-based DAPT and abbreviated DAPT followed by potent P2Y<sub>12</sub> inhibitor monotherapy are increasingly adopted to mitigate bleeding risk. However, their relative efficacy and safety remain uncertain.</p><p><strong>Methods and results: </strong>Network meta-analyses of randomized controlled trials were performed to compare three guideline-endorsed strategies: (i) short-term potent P2Y<sub>12</sub> inhibitor-based DAPT de-escalation to clopidogrel-based DAPT, (ii) abbreviated DAPT followed by potent P2Y<sub>12</sub> inhibitor monotherapy, and (iii) standard 12-month potent P2Y<sub>12</sub> inhibitor-based DAPT. The primary efficacy endpoint was major adverse cardiovascular events (MACE). Secondary efficacy endpoints included all-cause mortality, cardiovascular mortality, myocardial infarction, stent thrombosis, and stroke. The primary safety endpoint was major bleeding. The key net clinical endpoint was net adverse clinical events (NACE). PROSPERO (CRD420251144892) Seven randomized controlled trials involving 20 673 patients were included. Both the de-escalation and abbreviation strategies significantly reduced major bleeding (RR 0.43, 95% CI 0.25-0.74, <i>P</i> = 0.002; and RR 0.43, 95% CI 0.33-0.58, <i>P</i> < 0.001, respectively) and NACE (RR 0.54, 95% CI 0.41-0.70, <i>P</i> < 0.001; and RR 0.72, 95% CI 0.61-0.84, <i>P</i> < 0.001, respectively) without increasing MACE or other ischaemic outcomes. Indirect comparison indicated that de-escalation vs. abbreviation strategies demonstrated comparable MACE, NACE, and bleeding outcomes.</p><p><strong>Conclusion: </strong>Following ACS, both de-escalation to clopidogrel-based DAPT and abbreviated DAPT followed by potent P2Y<sub>12</sub> inhibitor monotherapy effectively reduce bleeding risk without compromising ischaemic protection. Given that the only available comparison between the two simplified strategies was indirect and showed comparable MACE and NACE outcomes, further research is warranted to determine the optimal individualized approach.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 5","pages":"oeag173"},"PeriodicalIF":4.3,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13712191/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149291328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Premature ventricular contractions: pathophysiology, prognostic impact, and management.","authors":"Raffaele Scorza, Pasquale Santangeli","doi":"10.1093/ehjopen/oeag164","DOIUrl":"https://doi.org/10.1093/ehjopen/oeag164","url":null,"abstract":"<p><p>Premature ventricular contractions (PVCs) arise from an early depolarization originating in either of the cardiac ventricles. They are common in individuals both with and without structural heart disease, although their true prevalence remains uncertain. Several electrophysiological mechanisms can initiate the PVC, with re-entry being the most frequent. The detection of PVCs should prompt a thorough clinical evaluation to identify potential underlying cardiac disease, yet many PVCs ultimately prove to be idiopathic. In individuals with established structural heart disease, PVCs have been associated with a poorer prognosis; however, clinical trials aimed at suppressing PVCs in this population have not demonstrated improved outcomes. In contrast, the prognostic significance of PVCs in patients without structural heart disease remains unclear. Factors such as PVC burden, PVC morphology, and cardiac magnetic resonance findings have been proposed as prognostic markers, although the evidence is still debated. In general, patients without structural heart disease and with a low PVC burden can be reassured regarding their prognosis. Treatment is primarily guided by symptoms, although reducing PVC burden may be considered even in asymptomatic individuals to mitigate the risk of complications such as PVC-induced cardiomyopathy or PVC-triggered sustained ventricular arrhythmias. Antiarrhythmic drugs are commonly used as first-line therapy, and the choice of medication should take into account patient characteristics, suspected pathophysiology, and PVC features. Catheter ablation (CA) is more effective than pharmacologic therapy in reducing or eliminating PVCs and may be considered as a first-line option in specific situations where rapid PVC suppression is desired. As an invasive procedure, CA carries potential risks that must be weighed carefully. Operator experience, PVC origin, anatomical considerations, and patient preference all play important roles in decision-making. Further research is needed to better identify patients at risk and to target specific pathophysiological mechanisms. Advances in device-based, patient-driven arrhythmia monitoring and the integration of artificial intelligence are likely to influence future PVC diagnostics and risk stratification.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 5","pages":"oeag164"},"PeriodicalIF":4.3,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13695076/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149278927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Psychiatric comorbidity and disparities in the invasive management of acute myocardial infarction: a national analysis, 2016-23.","authors":"Viswanadh Polana, Vikasa Godishala, Divyasri Koneru, Siddharth Karipineni, Simran Tanna, Nishant Patel, Dhairya Nanavaty, Sohrab Singh, Cesar Ayala-Rodriguez, Sarath Reddy","doi":"10.1093/ehjopen/oeag171","DOIUrl":"https://doi.org/10.1093/ehjopen/oeag171","url":null,"abstract":"<p><strong>Aims: </strong>Mental health disorders (MHDs) are common in acute myocardial infarction (AMI) and have been associated with less intensive cardiac care. We examined trends in five MHDs and their adjusted associations with in-hospital mortality, mechanical circulatory support (MCS), and coronary revascularization.</p><p><strong>Methods and results: </strong>We analysed the National Inpatient Sample, 2016-23, including adult hospitalizations with a principal diagnosis of AMI [ICD-10-CM I21.x/I22.x, excluding type 2 myocardial infarction (MI)]; five MHDs were identified from secondary diagnoses. Survey-weighted logistic regression produced adjusted odds ratios (aORs), adjusting for demographics, hospital characteristics, MI type, and 19 comorbidities, with all five MHDs entered simultaneously. Sensitivity analyses were restricted to hospitalizations without prior MI, percutaneous coronary intervention, or coronary artery bypass grafting. Among 970 969 AMI hospitalizations, prevalence rose for every MHD except schizophrenia/psychotic disorders, most steeply for PTSD (Post-traumatic stress disorder). Schizophrenia/psychotic disorders had the lowest adjusted odds of revascularization [aOR, 0.56; 95% confidence interval, 0.53-0.60] and invasive management (0.52; 0.49-0.55), followed by bipolar disorder (revascularization 0.81; 0.78-0.85); MCS associations were attenuated after adjustment. Restricted to those without prior coronary disease, the schizophrenia deficit was larger (0.54; 0.50-0.57) than among those with prior coronary disease (0.67; 0.60-0.74; interaction <i>P</i> < 0.001). Depression, anxiety, bipolar disorder, and PTSD were associated with lower adjusted in-hospital mortality (all <i>P</i> < 0.001); schizophrenia/psychotic disorders showed no significant difference (1.11; 0.98-1.26; <i>P</i> = 0.09).</p><p><strong>Conclusion: </strong>Schizophrenia and other psychotic disorders were consistently associated with markedly lower odds of invasive evaluation and coronary revascularization after AMI, with the largest deficit at first presentation. These findings highlight a potentially modifiable gap in cardiovascular care.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 6","pages":"oeag171"},"PeriodicalIF":4.3,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13759986/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149414289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Annett Salzwedel, Johannes A Vey, Birna Bjarnason-Wehrens, Axel Schlitt, Bernhard Schwaab, Elena Tessitore, Amina Cheikh Rouhou, David Niederseer, Mahdi Sareban, Greta Hametner, Maria-Inti Metzendorf, Gloria Petrasch, Steffen Schneider, Jean-Paul Schmid, Bernhard Rauch, Constantinos H Davos
{"title":"Beneficial effects of cardiac rehabilitation after acute coronary syndrome and coronary artery bypass grafting: Real-world evidence from the Cardiac Rehabilitation Outcome Study update (CROS-III).","authors":"Annett Salzwedel, Johannes A Vey, Birna Bjarnason-Wehrens, Axel Schlitt, Bernhard Schwaab, Elena Tessitore, Amina Cheikh Rouhou, David Niederseer, Mahdi Sareban, Greta Hametner, Maria-Inti Metzendorf, Gloria Petrasch, Steffen Schneider, Jean-Paul Schmid, Bernhard Rauch, Constantinos H Davos","doi":"10.1093/ehjopen/oeag152","DOIUrl":"https://doi.org/10.1093/ehjopen/oeag152","url":null,"abstract":"<p><strong>Aims: </strong>To review the effects of cardiac rehabilitation (CR) in patients with acute coronary syndrome (ACS), coronary artery bypass grafting (CABG) and in mixed populations treated with contemporary interventional, surgical and pharmacological therapy.</p><p><strong>Methods and results: </strong>A systematic review and meta-analysis (PROSPERO CRD42025630588) including randomized controlled trials (RCT) and prospective/retrospective controlled cohort studies (pCCS/rCCS) was performed with total mortality as main endpoint. Additional endpoints were cardiovascular mortality, non-fatal cardiovascular events, and hospital readmissions. Subgroup analysis was performed for age and sex. From 40 included studies, 29 studies encompassing 308 514 patients were eligible for this meta-analysis, including 5 newly identified (published between 11/2018-09/2025) studies with 92 571 patients. In pCCS and rCCS, CR-participation was associated with significantly reduced total mortality in patients with ACS (<i>n</i> = 41 740; pCCS: HR 0.33, 95% CI 0.15-0.69; rCCS: HR 0.64, 95% CI 0.55-0.75) and with CABG (<i>n</i> = 17 998; rCCS: HR 0.65, 95% CI 0.56-0.76). The effects regarding total mortality were similar in sex and age subgroups. Cardiovascular mortality and non-fatal stroke were decreased in ACS and CABG patients. In mixed populations, CR was associated with reduced hospital readmissions for any reason and for any cardiovascular event. Methodological and structural heterogeneity and low patient numbers prevented robust results.</p><p><strong>Conclusion: </strong>Based on observational data, participation in CR is associated with an improved prognosis in current patients after ACS, CABG and mixed populations, similarly for sex and age subgroups. Hence, CR should be an integral part of secondary prevention in those patients. Nevertheless, high-quality studies are needed to increase the CR evidence base further.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 5","pages":"oeag152"},"PeriodicalIF":4.3,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13714604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149303272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Stefan Salzmann, Kilian Stenzel, Max Berg, Jochen Senges, Christopher M Celano, Jeff C Huffman, Martin Borggrefe, Ibrahim Akin, Dierk Thomas, Christopher Jan Schwarzbach, Thomas Kleemann, Steffen Schneider, Matthias Hochadel, Tim Süselbeck, Harald Schwacke, Angelika Alonso, Markus Haass, Karl-Heinz Ladwig, Christoph Herrmann-Lingen, Monika Sadlonova
{"title":"Psychosocial symptom networks across atrial fibrillation subtypes: evidence from two waves of the ARENA cohort.","authors":"Stefan Salzmann, Kilian Stenzel, Max Berg, Jochen Senges, Christopher M Celano, Jeff C Huffman, Martin Borggrefe, Ibrahim Akin, Dierk Thomas, Christopher Jan Schwarzbach, Thomas Kleemann, Steffen Schneider, Matthias Hochadel, Tim Süselbeck, Harald Schwacke, Angelika Alonso, Markus Haass, Karl-Heinz Ladwig, Christoph Herrmann-Lingen, Monika Sadlonova","doi":"10.1093/ehjopen/oeag166","DOIUrl":"10.1093/ehjopen/oeag166","url":null,"abstract":"<p><strong>Aims: </strong>Atrial fibrillation (AF) carries substantial psychosocial burden, but how psychosocial symptoms interrelate across AF subtypes and severities remains unclear. This study compared psychosocial symptom networks across time, AF type, and European Heart Rhythm Association (EHRA) class in the ARENA (Atrial Fibrillation Rhine-Neckar Region) cohort.</p><p><strong>Methods and results: </strong>Adults with AF were assessed at baseline (T0) and follow-up (T1). Analytic samples included 996 patients with EHRA class [asymptomatic (EHRA 1) vs. symptomatic (EHRA ≥ 2)] and 924 with AF subtype (paroxysmal, persistent, or permanent) data. Measures included anxiety and worry (GAD-2), cardiac worry and avoidance (CAQ-2), health-related quality of life (HRQoL) (EQ-5D-5L), and psychosocial stressors. Gaussian graphical models were estimated and compared using network comparison test. Global network structures were stable across EHRA classes, AF subtypes, and time points, but specific edges and node centralities varied. The most robust edges linked anxiety with general worry and cardiac worry with avoidance. Anxiety, general worry, cardiac worry, and diminished HRQoL were consistently the most central nodes. Among symptomatic (EHRA ≥ 2) patients, loneliness emerged as an increasingly central node over time, whereas among asymptomatic patients (EHRA 1), sleep problems showed a stronger association with HRQoL at follow-up. Atrial fibrillation-type network structures were similar, although paroxysmal networks showed higher node centrality and stronger anxiety-worry coupling at T0; persistent or permanent AF showed a stress-at-home-cardiac worry edge at T1.</p><p><strong>Conclusion: </strong>Psychosocial symptom networks in AF are comparable across subtypes and reveal intervention targets, particularly anxiety, cardiac worry with avoidance, loneliness, and sleep disturbance.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 6","pages":"oeag166"},"PeriodicalIF":4.3,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13739053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149345207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ramin Ebrahimi, Shaojie Chen, Davide Di Vece, Michele Maremmani, Ali Mahdi, Bahira Shahim, Jan Hendrik Niess, Alexander Kutz, Fahim Ebrahimi, Anders Forss
{"title":"Adverse arrhythmia-related outcomes after catheter ablation in patients with inflammatory bowel disease: a nationwide propensity score-matched cohort study.","authors":"Ramin Ebrahimi, Shaojie Chen, Davide Di Vece, Michele Maremmani, Ali Mahdi, Bahira Shahim, Jan Hendrik Niess, Alexander Kutz, Fahim Ebrahimi, Anders Forss","doi":"10.1093/ehjopen/oeag168","DOIUrl":"10.1093/ehjopen/oeag168","url":null,"abstract":"<p><strong>Aims: </strong>Inflammatory bowel diseases (IBD) have been associated with an increased long-term risk of arrhythmia. However, clinical outcomes following catheter ablation in patients with IBD are unknown.</p><p><strong>Methods and results: </strong>In this nationwide Swiss cohort study of adults undergoing catheter ablation for arrhythmia between 2012 and 2022, patients with IBD were propensity score-matched 1:10 to comparators without IBD. The primary endpoint was a composite of the first occurrence of any of the following events: reablation, cardioversion, or hospitalization for arrhythmia. Secondary endpoints were each individual component of the primary endpoint. An additional win ratio-based hierarchical analysis was performed. Hazard ratios (HRs) and incidence rates (IRs) were calculated using Cox proportional hazards modelling. A total of 251 patients with IBD and 2429 matched comparators were included in the study. After a median follow-up time of 2.6 years (IQR 0.8-5.6), the primary endpoint occurred in 81 (32.3%, IR: 100.8/1000 person-years) patients with IBD and in 640 (26.3%, IR: 73.3/1000 person-years) matched comparators, yielding an HR of 1.30 [95% confidence interval (CI) = 1.03-1.64]. Among the individual components of the primary endpoint, hospitalization for arrhythmia was more frequent in patients with IBD (HR 1.29, 95% CI = 1.02-1.64), while the remaining components did not differ between groups. In hierarchical win ratio analysis, patients with IBD had worse composite outcomes than matched comparators (win ratio 0.80, 95% CI = 0.65-0.99, <i>P</i> = 0.04).</p><p><strong>Conclusion: </strong>Patients with IBD undergoing catheter ablation exhibited 30% higher hazards of adverse arrhythmia-related outcomes.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 6","pages":"oeag168"},"PeriodicalIF":4.3,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13739052/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149345194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ksenia Sedova, Jan Azarov, Peter M Van Dam, Karol Curila, Pavel Leinveber, Josef Kautzner
{"title":"Optimal depolarization sequence for cardiac resynchronization therapy patients.","authors":"Ksenia Sedova, Jan Azarov, Peter M Van Dam, Karol Curila, Pavel Leinveber, Josef Kautzner","doi":"10.1093/ehjopen/oeag165","DOIUrl":"https://doi.org/10.1093/ehjopen/oeag165","url":null,"abstract":"<p><strong>Aims: </strong>Electrical ventricular dyssynchrony is a hallmark of intraventricular conduction disease in heart failure with reduced ejection fraction. Although cardiac resynchronization therapy (CRT) is effective, a proportion of patients with electrical dyssynchrony evidenced by an electrocardiogram (ECG) remain non-responders. Besides the QRS duration, visualization and quantification of the depolarization sequence could contribute to improving CRT response. The study aimed to evaluate the CineECG-derived mean temporo-spatial isochrone trajectory of depolarization in CRT patients.</p><p><strong>Methods and results: </strong>Among the adult cohort of 121 patients who underwent CRT implantation, there were 93 (33% female) responders and 28 (7% female) non-responders. ECGs recorded before and immediately after CRT implantation were collected and analysed using the CineECG modality with a generic heart/torso model. The CineECG-derived path directions were computed for the QRS on anteroposterior, interventricular, and apicobasal axes within the cardiac anatomy. Spatial depolarization characteristics were tested for the association with left ventricle reverse-remodelling at 6-month follow-up. The pre-implantation depolarization sequence was predominantly from the right to the left ventricle, and after the CRT implant, it has been transformed into an apicobasal direction. In multivariate logistic regression, the pre-implant QRS duration, apicobasal depolarization gradient, and CRT-induced QRS shortening independently predicted CRT response. The Akaike information criterion indicated that combining all three yielded the strongest predictive model.</p><p><strong>Conclusion: </strong>CineECG-derived depolarization gradients, which reflect ventricular activation sequence, changed significantly after CRT, and the pre-implantation apicobasal gradient independently predicted echocardiographic outcome, with a less pronounced gradient associated with better haemodynamic response.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 5","pages":"oeag165"},"PeriodicalIF":4.3,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13689692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149279037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ramesh Nadarajah, Ali Wahab, Ben Hurdus, Carl Simela, Tobin Joseph, Catherine Reynolds, Sheena Bennet, Mohammad Haris, Louise Clark, Chris Hayward, Jing Kang, Jianhua Wu, Chris P Gale
{"title":"Specialist-led community-based cardio-kidney-metabolic-pulmonary care in high-risk individuals: multi-centre pragmatic prospective randomized open-label blinded endpoint trial.","authors":"Ramesh Nadarajah, Ali Wahab, Ben Hurdus, Carl Simela, Tobin Joseph, Catherine Reynolds, Sheena Bennet, Mohammad Haris, Louise Clark, Chris Hayward, Jing Kang, Jianhua Wu, Chris P Gale","doi":"10.1093/ehjopen/oeag169","DOIUrl":"https://doi.org/10.1093/ehjopen/oeag169","url":null,"abstract":"<p><strong>Aims: </strong>Pharmacological therapies that treat cardiovascular, kidney, metabolic, and pulmonary (CKMP) risk factors reduce the risk of major adverse cardiovascular events, but community-dwelling individuals may not receive all treatments to which they are eligible from non-specialists. This trial investigated if specialist-led care in the community increases the utilization of CKMP pharmacological interventions compared with usual care.</p><p><strong>Methods and results: </strong>This pragmatic prospective randomized open-label blinded endpoint trial included community-dwelling high-risk adults aged ≥30 years from 15 primary care sites in England. Participants were randomized 1:1 to an intervention of two clinic appointments (at baseline and ∼3 months) with a cardiology specialist at their primary care site to review and optimize CKMP risk factors in accordance with UK guidelines, or usual care. The primary outcome was the proportion of participants with initiation and/or increase in the dose of guideline-directed CKMP pharmacological therapies at 6 months after date of randomization. Between March 2025 and July 2025, 138 participants were randomized (68 intervention, 70 control); the median age was 76.6 years, and 52.9% were women. At 6 months after randomization, in the intervention arm, 42 of 68 (61.8%) patients received a CKMP pharmacological intervention compared with 16 of 70 patients (22.9%) in the control arm (odds ratio 5.4, 95% CI 2.5-12.3, <i>P</i> < 0.0001, absolute risk difference 38.9%, 95% CI 23.7-54.1%).</p><p><strong>Conclusion: </strong>Specialist-led care in the community for high-risk individuals increased the use of pharmacological interventions for CKMP risk factors compared to usual care.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 5","pages":"oeag169"},"PeriodicalIF":4.3,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13712192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149291331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Risk stratification of Stage B heart failure with BNP levels of 35-100 pg/mL: development of the PHASE Index from the CHART-2 Study.","authors":"Hiroyuki Takahama, Kotaro Nochioka, Satoshi Miyata, Hideka Hayashi, Takumi Inoue, Kai Susukita, Kazuma Oyama, Takashi Shiroto, Jun Takahashi, Hiroaki Shimokawa, Satoshi Yasuda","doi":"10.1093/ehjopen/oeag160","DOIUrl":"https://doi.org/10.1093/ehjopen/oeag160","url":null,"abstract":"<p><strong>Aims: </strong>B-type natriuretic peptide (BNP) levels of 35-100 pg/mL, common in preclinical heart failure (HF), are associated with heterogeneous prognosis and are influenced by age and renal function. We aimed to characterize risk heterogeneity in preclinical HF patients with BNP levels of 35-100 pg/mL and to develop a practical risk stratification model.</p><p><strong>Methods and results: </strong>Data from the Chronic Heart Failure Registry and Analysis in the Tohoku District-2 (CHART-2) Study, a prospective multicentre cohort with long-term follow-up, were analysed. Among patients with Stage B HF (<i>n</i> = 4074; age 67.6 ± 12.0 years), the predictability of BNP for 10-year HF-related events was evaluated across strata of age and estimated glomerular filtration rate (eGFR). In patients with BNP levels of 35-100 pg/mL, a composite risk score-the Pre-Heart Failure Assessment and Screening Evaluation (PHASE) Index-was developed using classification and regression tree analysis and multivariable Cox proportional hazards modelling. BNP discrimination varied significantly by age and eGFR (<i>P</i> < 0.05), indicating that a single BNP threshold is insufficient for risk stratification in preclinical HF. The PHASE Index, incorporating age, BNP, eGFR, left ventricular ejection fraction, body mass index, and hypertension, stratified patients with BNP levels of 35-100 pg/mL into four categories and demonstrated superior discrimination compared with BNP alone (c-index 0.723 vs. 0.587, <i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>Patients with preclinical HF and BNP levels of 35-100 pg/mL exhibit substantial risk heterogeneity. The PHASE Index improves identification of high-risk individuals and provides a pragmatic tool for risk stratification beyond the conventional BNP threshold.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 5","pages":"oeag160"},"PeriodicalIF":4.3,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13663803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}